Wang, W. Q., Ge, J., Ma, H. H., Lian, H. Y., Cui, L., Zhang, L., . . . Zhang, R. (2023). Efficacy and safety of intermediate-dose cytarabine in the treatment of children with refractory high risk Langerhans cell histiocytosis. Zhonghua er ke za zhi = Chinese journal of pediatrics, 61(12), 1118. https://doi.org/10.3760/cma.j.cn112140-20230928-00231
Style de citation ChicagoWang, W Q., J. Ge, H H. Ma, H Y. Lian, L. Cui, L. Zhang, Z G. Li, T Y. Wang, et R. Zhang. "Efficacy and Safety of Intermediate-dose Cytarabine in the Treatment of Children with Refractory High Risk Langerhans Cell Histiocytosis." Zhonghua Er Ke Za Zhi = Chinese Journal of Pediatrics 61, no. 12 (2023): 1118. https://dx.doi.org/10.3760/cma.j.cn112140-20230928-00231.
Style de citation MLAWang, W Q., et al. "Efficacy and Safety of Intermediate-dose Cytarabine in the Treatment of Children with Refractory High Risk Langerhans Cell Histiocytosis." Zhonghua Er Ke Za Zhi = Chinese Journal of Pediatrics, vol. 61, no. 12, 2023, p. 1118.